Related references
Note: Only part of the references are listed.250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor
LANCET NEUROLOGY (2012)
The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis
V. Devonshire et al.
EUROPEAN JOURNAL OF NEUROLOGY (2011)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2011)
Anti-JC Virus Antibodies: Implications for PML Risk Stratification
Leonid Gorelik et al.
ANNALS OF NEUROLOGY (2010)
Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis
Ralf A. Linker et al.
BRAIN (2010)
Development of oral cladribine for the treatment of multiple sclerosis
Hans-Peter Hartung et al.
JOURNAL OF NEUROLOGY (2010)
JCV detection in multiple sclerosis patients treated with natalizumab
Saud A. Sadiq et al.
JOURNAL OF NEUROLOGY (2010)
Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study
Samantha Jilek et al.
LANCET NEUROLOGY (2010)
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases
David B. Clifford et al.
LANCET NEUROLOGY (2010)
Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis
Chen S. Tan et al.
LANCET NEUROLOGY (2010)
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results
G. Comi et al.
MULTIPLE SCLEROSIS (2010)
The mechanism of action of glatiramer acetate treatment in multiple sclerosis
Michael K. Racke et al.
NEUROLOGY (2010)
Interferon-β mechanisms of action in multiple sclerosis
Suhayl Dhib-Jalbut et al.
NEUROLOGY (2010)
Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS
E. Kingwell et al.
NEUROLOGY (2010)
Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
James J. Marriott et al.
NEUROLOGY (2010)
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Gavin Giovannoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence
Francesco Patti
Patient Preference and Adherence (2010)
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases (vol 9, pg 438, 2010)
D. B. Clifford et al.
LANCET NEUROLOGY (2010)
Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
Kathleen Hawker et al.
ANNALS OF NEUROLOGY (2009)
Identification and Characterization of Mefloquine Efficacy against JC Virus In Vitro
Margot Brickelmaier et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis
Aaron Boster et al.
ARCHIVES OF NEUROLOGY (2009)
ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis
S. Cotte et al.
BRAIN (2009)
FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system
Volker Brinkmann
BRITISH JOURNAL OF PHARMACOLOGY (2009)
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
Michael Hutchinson et al.
JOURNAL OF NEUROLOGY (2009)
Concepts of induction and escalation therapy in multiple sclerosis
Peter Rieckmann
JOURNAL OF THE NEUROLOGICAL SCIENCES (2009)
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
G. Comi et al.
LANCET (2009)
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
Eva Havrdova et al.
LANCET NEUROLOGY (2009)
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
Ludwig Kappos et al.
LANCET NEUROLOGY (2009)
Efficacy of treatment of MS with IFNβ-1b or glatiramer acetate by monthly brain MRI in the BECOME study
D. Cadavid et al.
NEUROLOGY (2009)
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function
B. O. Khatri et al.
NEUROLOGY (2009)
Oral fingolimod (FTY720) in multiple sclerosis Two-year results of a phase II extension study
P. O'Connor et al.
NEUROLOGY (2009)
Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab
Yiping Chen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
Werner Wenning et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Progressive Multifocal Leukoencephalopathy after Natalizumab Monotherapy
Hans Linda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Adaptive Mutations in the JC Virus Protein Capsid Are Associated with Progressive Multifocal Leukoencephalopathy (PML)
Shamil R. Sunyaev et al.
PLOS GENETICS (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
Paul O'Connor et al.
LANCET NEUROLOGY (2009)
Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab
Maria del Pilar Martin et al.
ARCHIVES OF NEUROLOGY (2008)
Reversible cystoid macular edema secondary to fingolimod in a renal transplant recipient
Georges Saab et al.
ARCHIVES OF OPHTHALMOLOGY (2008)
Disability and T2 MRI lesions:: a 20-year follow-up of patients with relapse onset of multiple sclerosis
L. K. Fisniku et al.
BRAIN (2008)
Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS
Douglas L. Arnold et al.
JOURNAL OF NEUROLOGY (2008)
Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations
H. Wiendl et al.
JOURNAL OF NEUROLOGY (2008)
Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients
Emmanuelle Le Page et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2008)
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Daniel D. Mikol et al.
LANCET NEUROLOGY (2008)
Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study
E. Cocco et al.
MULTIPLE SCLEROSIS JOURNAL (2008)
Induction and add-on therapy with Mitoxantrone and Interferon beta in multiple sclerosis
Mauro Zaffaroni et al.
NEUROLOGICAL SCIENCES (2008)
Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis
E. Cocco et al.
MULTIPLE SCLEROSIS JOURNAL (2007)
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis:: a 3-year follow-up analysis of the BENEFIT study
Ludwig Kappos et al.
LANCET (2007)
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring
Ludwig Kappos et al.
LANCET NEUROLOGY (2007)
The immunopathology of multiple sclerosis:: An overview
Hans Lassmann et al.
BRAIN PATHOLOGY (2007)
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
Jerry S. Wolinsky et al.
ANNALS OF NEUROLOGY (2007)
Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis - A systematic review
Annette Langer-Gould et al.
ARCHIVES OF NEUROLOGY (2006)
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
L. Kappos et al.
NEUROLOGY (2006)
Baseline MRI predicts future attacks and disability in clinically isolated syndromes
M. Tintore et al.
NEUROLOGY (2006)
Oral fingolimod (FTY720) for relapsing multiple sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis
Jason Ramtahal et al.
JOURNAL OF NEUROLOGY (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
RA Rudick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Diagnostic criteria for multiple sclerosis: 2005 Revisions to the McDonald Criteria
CH Polman et al.
ANNALS OF NEUROLOGY (2005)
Multiple sclerosis:: Mitoxantrone promotes differential effects on immunocompetent cells in vitro
O Neuhaus et al.
JOURNAL OF NEUROIMMUNOLOGY (2005)
Brief report - Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis
BK Kleinschmidt-DeMasters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Brief report - Progressive multifocal leukoencephalopathy in a patient treated with natalizumab
A Langer-Gould et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
DNA topoisomerase II in therapy-related acute promyelocytic leukemia
AR Mistry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients
A Chan et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2005)
The human polyomavirus, JCV, uses serotonin receptors to infect cells
GF Elphick et al.
SCIENCE (2004)
Interrupted therapy -: Stopping and switching of the β-interferons prescribed for MS
HL Tremlett et al.
NEUROLOGY (2003)
Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trial
HP Hartung et al.
LANCET (2002)
Randomized, comparative study of interferon β-1a treatment regimens in MS -: The EVIDENCE trial
H Panitch et al.
NEUROLOGY (2002)
Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time
T Kuhlmann et al.
BRAIN (2002)
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
JA Cohen et al.
NEUROLOGY (2002)
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)
L Durelli et al.
LANCET (2002)
Disease modifying therapies in multiple sclerosis - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
DS Goodin et al.
NEUROLOGY (2002)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
WI McDonald et al.
ANNALS OF NEUROLOGY (2001)
Randomized controlled trial of interferon-beta-1a in secondary progressive MS - MRI results
DKB Li et al.
NEUROLOGY (2001)
Effect of early interferon treatment on conversion to definite multiple sclerosis:: a randomised study
G Comi et al.
LANCET (2001)
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis
G Comi et al.
ANNALS OF NEUROLOGY (2001)
Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability
N De Stefano et al.
ARCHIVES OF NEUROLOGY (2001)
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis.
LD Jacobs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Cladribine and progressive MS - Clinical and MRI outcomes of a multicenter controlled trial
GPA Rice et al.
NEUROLOGY (2000)
Share Paper
